You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 282 No. 6, August 11, 1999 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Editorial
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (19)
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in JAMA
 Topic Collections
 •HIV/AIDS
 •Immunology
 •Immunologic Disorders
 •Infectious Diseases
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Can Perinatal HIV Infection Be Eliminated in the United States?

Lynne M. Mofenson, MD

JAMA. 1999;282:577-579.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In February 1994, the results of a clinical trial that would change the face of the pediatric human immunodeficiency virus (HIV) epidemic in the United States were announced. The trial, Pediatric AIDS Clinical Trials Group (PACTG) protocol 076, demonstrated that a zidovudine regimen given to HIV-infected women during pregnancy and labor and to the neonate for the first 6 weeks of life could reduce the risk of perinatal transmission by two thirds—from 26% in placebo to 8% in zidovudine recipients.1

This trial provided the first major breakthrough in the prevention of HIV transmission. A US Public Health Service task force was rapidly convened to develop guidelines for the use of zidovudine to reduce perinatal transmission; these guidelines were published in August 1994.2 Significant declines in perinatal transmission were observed as early as 1995 due to the rapid incorporation of this regimen into clinical practice.3 While it . . . [Full Text of this Article]

Author Affiliation: Pediatric, Adolescent and Maternal AIDS Branch, National Institute of Child Health and Human Development, National Institutes of Health, Rockville, Md.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLES

Trends in Perinatal Transmission of HIV/AIDS in the United States
, , , , , , , , and
JAMA. ;282():531-538.
FULL TEXT  

Don't pass on HIV to your child
JAMA. ;282():606-606.
 


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Synergy between mannose-binding lectin gene polymorphisms and supplementation with vitamin A influences susceptibility to HIV infection in infants born to HIV-positive mothers.
Kuhn et al.
Am. J. Clin. Nutr. 2006;84:610-615.
ABSTRACT | FULL TEXT  

Changing Epidemiology of Perinatal HIV-1 Infection in the United States
Shetty and Maldonado
NeoReviews 2001;2:e94-99.
FULL TEXT  

Technical Report: Perinatal Human Immunodeficiency Virus Testing and Prevention of Transmission
Mofenson and the Committee on Pediatric AIDS
Pediatrics 2000;106:88e-88.
ABSTRACT | FULL TEXT  

Cost-Effectiveness of Universal Compared With Voluntary Screening for Human Immunodeficiency Virus Among Pregnant Women in Chicago
Immergluck et al.
Pediatrics 2000;105:54e-54.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1999 American Medical Association. All Rights Reserved.